INmune Bio, Inc. INMB
2.03
0.03
1.50%
as of 25 Sep
- Market cap
- $55.5M
- P/E
- 0.0×
Follow INMB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.94 | 4.11 | 3.48 | 4.10 | |
Current Ratio |
4.04 | 4.24 | 3.55 | 4.17 | |
Net Debt/EBITDA |
13.06 | 3.71 | 4.57 | 3.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.49 | 0.63 | 0.56 | 0.84 | |
Capex/Depreciation |
(6.52) | 0.00 | (2.55) | (6.89) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.12) | (0.13) | (0.12) | (0.20) | |
Capex per Share |
(0.02) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.13) | (0.13) | (0.12) | (0.21) | |
Cash per Share |
0.69 | 0.80 | 1.00 | 1.04 | |
Shareholders Equity per Share |
0.76 | 0.74 | 0.95 | 0.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.76 | 0.74 | 0.95 | 0.95 | |
Free Cash Flow |
(3.60) | (3.40) | (3.09) | (5.63) | |
Working Capital |
17.91 | 17.43 | 21.47 | 23.31 | |
Capital Expenditures |
(0.43) | — | (0.14) | (0.19) | |
Net Current Asset Value |
17.32 | 16.63 | 21.06 | 22.69 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
3.46 | 1.09 | 2.98 | 1.94 | |
Average Payables |
6.47 | 5.99 | 7.18 | 8.77 | |
Average Assets |
32.26 | 31.81 | 35.96 | 43.07 | |
Average Common Equity |
24.61 | 24.65 | 27.81 | 32.03 |
Columns are period end dates